

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Durso-Bumpus Debra</u>			2. Issuer Name and Ticker or Trading Symbol <u>Blueprint Medicines Corp [BPMC]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) _____ CHIEF PEOPLE OFFICER		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>06/21/2024</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET			4. If Amendment, Date of Original Filed (Month/Day/Year)			Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		
(Street)	(City)	(State)	(Zip)					
CAMBRIDGE	MA		02139					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/21/2024		M ⁽¹⁾		13,741	A	\$18	71,056	D	
Common Stock	06/21/2024		M ⁽¹⁾		7,041	A	\$18	78,097	D	
Common Stock	06/21/2024		M ⁽¹⁾		24,200	A	\$36.05	102,297	D	
Common Stock	06/21/2024		M ⁽¹⁾		15,500	A	\$54.13	117,797	D	
Common Stock	06/21/2024		S ⁽¹⁾		1,567	D	\$105.82 ⁽²⁾	116,230	D	
Common Stock	06/21/2024		S ⁽¹⁾		18,752	D	\$104.98 ⁽³⁾	97,478	D	
Common Stock	06/21/2024		S ⁽¹⁾		40,353	D	\$104.14 ⁽⁴⁾	57,125	D	
Common Stock	06/21/2024		S ⁽¹⁾		13,062	D	\$103.05 ⁽⁵⁾	44,063	D	
Common Stock	06/21/2024		S ⁽¹⁾		300	D	\$102.44 ⁽⁶⁾	43,763	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$18	06/21/2024		M ⁽¹⁾			13,471	(7)	04/27/2025	Common Stock	13,471	\$0	0	D	
Stock Option (Right to Buy)	\$18	06/21/2024		M ⁽¹⁾			7,041	(7)	04/27/2025	Common Stock	7,041	\$0	0	D	
Stock Option (Right to Buy)	\$36.05	06/21/2024		M ⁽¹⁾			24,200	(8)	02/16/2027	Common Stock	24,200	\$0	0	D	
Stock Option (Right to Buy)	\$54.13	06/21/2024		M ⁽¹⁾			15,500	(9)	03/01/2030	Common Stock	15,500	\$0	13,000	D	

Explanation of Responses:

- Effected pursuant to a trading plan adopted on March 13, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$105.53 to \$106.51 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (6) in this form 4.
- The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$104.52 to \$105.51 per share.
- The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$103.53 to \$104.51 per share.
- The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$102.51 to \$103.51 per share.
- The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$102.44 to \$102.45 per share.
- This option was granted on April 27, 2015 and is fully vested as of the transaction date.

8. This option was granted on February 16, 2017 and is fully vested as of the transaction date.

9. This option was granted on March 1, 2020 and is fully vested as of the transaction date.

/s/ Melissa Masse

06/25/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.